

# In the News: What We're Reading on 340B in New York

The federal 340B Drug Pricing Program was designed to support patients with the greatest need. But a growing body of reporting and research is raising concerns about whether the program is meeting that goal.

It's why legislators in New York must reject legislation that expands the program, and demand transparency to ensure the program benefits patients, not large hospitals, pharmacy benefit managers, and retail pharmacy chains.

An opinion article by the Washington Post Editorial Board sheds more light on how the 340B program is being misused by large tax-exempt hospitals at the expense of patients.

---

## **How corporate welfare for hospitals is raising health care costs** The Washington Post | By Editorial Board | April 18, 2026

...

Instead of serving as a safety net for hospitals in vulnerable communities, the program has become a profit-making venture for big businesses.

...

the program has fueled consolidation within the health care industry, as hospital systems seek to gobble up as many 340B-eligible patients as possible.

...

Once a business gets accustomed to handouts, it becomes extremely difficult to take them away. But it's a fight worth having."

See The Washington Post's full article [HERE](#).